Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
8.28
-0.29 (-3.38%)
Dec 20, 2024, 4:00 PM EST - Market closed

Y-mAbs Therapeutics Revenue

Y-mAbs Therapeutics had revenue of $18.46M in the quarter ending September 30, 2024, a decrease of -9.74%. This brings the company's revenue in the last twelve months to $84.55M, down -8.99% year-over-year. In the year 2023, Y-mAbs Therapeutics had annual revenue of $84.82M with 29.96% growth.

Revenue (ttm)
$84.55M
Revenue Growth
-8.99%
P/S Ratio
4.31
Revenue / Employee
$845,530
Employees
100
Market Cap
370.85M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202384.82M19.55M29.96%
Dec 31, 202265.27M30.37M87.03%
Dec 31, 202134.90M14.15M68.18%
Dec 31, 202020.75M--
Dec 31, 2019---
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Enhabit 1.04B
ZimVie 451.29M
Quanterix 129.33M
Personalis 87.49M
REGENXBIO 84.33M
Alpha Teknova 36.35M
Nano-X Imaging 10.68M
Taysha Gene Therapies 9.92M
Revenue Rankings